FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

Main Inclusion Criteria: 1. Adults (≥18 years) with Chronic Kidney Disease defined as: * eGFR ≥25 and \<120 mL/min/1.73 m2 using CKD-EPI 2009 formula at the Screening visit. * UACR ≥100 mg/g (11.3 mg/mmol) to \<5000 mg/g (565 mg/mmol) at the Screening visit (geometric mean of the 3 measurements) and documentation of elevated albuminuria or proteinuria. 2. Potassium level ≤5.0 mmol/L at Screening (local assessment). 3. No current or previous (within 8 weeks prior to the Screening visit) treatment with RAS inhibition (ACEi, ARB, or Renin inhibitor (e.g. Aliskiren)). Main Exclusion Criteria: 1. Participants with an HbA1c\>11%. 2. Participants with type 1 diabetes. 3. Symptomatic heart failure with reduced ejection fraction and class 1A indication for MRA treatment.